Navigation Links
FDA Approves First-of-its-Kind Drug to Treat Rare Blood Disorder

ilization of blood hemoglobin concentrations compared with no stabilization among placebo-treated patients. Soliris-treated patients also required significantly fewer blood transfusions.

Soliris' blockade of the body's natural immune system increases the patient's susceptibility to certain serious infections, particularly meningococcal infections that can cause bacterial meningitis, an infection of the tissue surrounding the spinal cord and brain. Serious meningococcal infection was the most important adverse reaction experienced by patients who received Soliris in clinical studies. Because of the high risk for serious meningococcal infections, all 196 PNH patients in the clinical studies were vaccinated with a meningococcal vaccine; two of them developed meningococcal sepsis (an infection of the bloodstream caused by meningococcal bacteria) during treatment with Soliris.

A special risk management plan for Soliris has been developed to address the risk of serious meningococcal infection. The labeling of the product contains a boxed warning and requires that patients receive meningococcal vaccination prior to receiving Soliris. The labeling also includes a Medication Guide for patients. In addition, the risk management plan includes an educational program for physicians.

Orphan products are developed to treat rare diseases or conditions that affect fewer than 200,000 people in the United States. The Orphan Drug Act provides a seven-year period of exclusive marketing to the first manufacturer who obtains marketing approval for a designated orphan product. About one person out of a million people will be diagnosed with PNH.

Source-Bio-Bio Technology
'"/>




Page: 1 2

Related medicine news :

1. FDA Approves Contraceptive Ring
2. FDA Approves New HIV Drug, Viread
3. FDA Approves Birth Control Skin Patch
4. FDA Approves New Arthritis Drug, Bextra
5. FDA Approves Elidel Cream for Eczema
6. FDA Approves New Anti-Clotting Drug
7. FDA Approves New surgery Treatment for Farsightedness
8. FDA Approves Anti-Cancer Cell Drug - Zevalin
9. FDA Approves Remodulin for Pulmonary Hypertension
10. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
11. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: FDA Approves First its Kind Drug Treat Rare Blood Disorder

(Date:3/30/2015)... (PRWEB) March 30, 2015 This ... has been designed to provide medical professionals with ... restrictions. Anatomy and physiology of fascia and its ... throughout the course. This PT CME course ... assessment and palpation skills to identify and treat ...
(Date:3/30/2015)... Mirada, CA (PRWEB) March 30, 2015 ... drug screens for employers and companies throughout ... job applicants are using drugs. It can identify ... illicit drugs. Employers, sports teams, D.O.T. applicants, and students ... , The features of the drug screen program ...
(Date:3/30/2015)... Join local United Methodists as they Rethink Church ... to provide healthcare for the 512 students at Raise ... on Saturday, April 18, at 9 a.m. at Edwin ... Road in Nashville. , Raise the Roof Academy in ... medical care. The nearest clinic is a three-hour walk. ...
(Date:3/30/2015)... (PRWEB) March 30, 2015 Foundations Recovery ... to announce the start of its 41st national conference ... Jane McGonigal, and former Congressman Patrick J. Kennedy as ... Conference being held in San Diego, CA, March 30 ... The national conference brings together leading experts specializing in ...
(Date:3/30/2015)... Sacramento, Calif. (PRWEB) March 30, 2015 ... and CDA, the CDA Cares free, two-day dental clinic ... to 2,080 people March 27-28. , In addition ... to Californians who experience barriers to care, CDA Cares ... good oral health and the need for an adequately ...
Breaking Medicine News(10 mins):Health News:North American Seminars received New Jersey and California approval for Myofascial Release - From Surface to the Depths, a PT and OT Continuing Education Course. 2Health News:Drug Screens Now at Healthpointe 2Health News:Drug Screens Now at Healthpointe 3Health News:Hike2Heal and Rethink Church Raise Funds To Provide Healthcare for Ugandan Children with 3rd Annual Raise the Roof 5K on April 18 2Health News:Foundations Recovery Network Kicks Off Its 41st National Conference Specializing in the Treatment of Substance Abuse and Behavioral Health 2Health News:CDA Cares Sacramento Dental Clinic Provides $2 Million in Care 2
... through an animal study that Aspartame can cause lymphoma, ... five 20-ounce bottles of diet soda sweetened with aspartame ... ,The study would be published in March issue ... journal., ,The method and sample adopted were feeding ...
... short breaks can go a long way in making ... study conducted by Massachusetts Institute researchers. // ... Massachusetts Institute of Technology in Cambridge, found that rats' ... pause briefly to rest., ,They suggest that eliminating ...
... cell research in the state with the approval of 61% ... have impeded the initiative. // ,The officials now ... will be initiated. Zach Hall, president of the California Institute ... would commence the project as soon as possible. ...
... Howard has allocated $1.1 billion in health reforms. But his ... ,Mr. Howard said that there was more mental illness previously ... thing is to move on with one’s life. ... ill-informed. ,Though he said that in reality mental ...
... Honolulu: The Hawaii State Hospital has gone down the ranks ... crowding, a status report has revealed//. The status report quotes, ... to meet the June 30th deadline, required to bring the ... had received a one-year extended timeframe till June 30 to ...
... the help of prisoners from Beur jail in Patna to ... near the jail and begged for money to fulfill the ... was kidnapped in Phulwarisharief while he was on his way ... to use their contacts outside the jail to help trace ...
Cached Medicine News:Health News:Task Learning Made Simple By Taking Short Breaks 2Health News:Momentum of Stem cell research impeded by legal challenges 2
(Date:3/30/2015)... 31 mars 2015  Une équipe de scientifiques chinois ... d,un récepteur de surface cellulaire qui joue ... thromboses. Contre toute attente, cette recherche a ... structurelles qui remettent en cause les idées ... récepteurs couplés aux protéines G (RCPG) et ...
(Date:3/30/2015)... Calif., March 30, 2015 Shareholder rights attorneys ... proposed acquisition of Hyperion Therapeutics, Inc. (NASDAQ: HPTX ... On March 30, 2015, the two companies announced the ... Horizon will acquire Hyperion.  Under the terms of the ... each share of Hyperion common stock. ...
(Date:3/30/2015)... , March 30, 2015 TapImmune ... its participation at the Fifth Annual "Cancer Immunotherapy: A Long-Awaited ... in New York City on ... Dr. Glynn Wilson , Chairman & CEO of ... to the Company.  Regrettably, due to parallel meeting sessions running behind ...
Breaking Medicine Technology:De nouvelles structures moléculaires remettent en cause les idées conventionnelles concernant l'action des médicaments sur les récepteurs 2De nouvelles structures moléculaires remettent en cause les idées conventionnelles concernant l'action des médicaments sur les récepteurs 3Robbins Arroyo LLP: Acquisition of Hyperion Therapeutics, Inc. (HPTX) by Horizon Pharma plc (HZNP) May Not Be in Shareholders' Best Interests 2Robbins Arroyo LLP: Acquisition of Hyperion Therapeutics, Inc. (HPTX) by Horizon Pharma plc (HZNP) May Not Be in Shareholders' Best Interests 3Presentation at the Maidstone Life Sciences "Cancer Immunotherapy: A Long-Awaited Reality" 2Presentation at the Maidstone Life Sciences "Cancer Immunotherapy: A Long-Awaited Reality" 3
... Percutaneous Administration (CUPID) Data Highlight Safety Profile and ... 26 Celladon Corporation today announced that results ... advanced heart failure, including Phase 1/2 data of ... Zsebo, PhD, President and CEO, Celladon Corporation and ...
... 26 Senesco Technologies, Inc. ("Senesco" or the "Company") ... mouse influenza survival studies that were conducted in Dr. William Scheld,s ... Mice treated with an siRNA against Senesco,s Factor 5A gene ... rate for mice that received no treatment or a control siRNA.A ...
Cached Medicine Technology:Celladon Corporation Announces Presentation of First-in-Human Gene Transfer to Treat Heart Failure at the 12th Annual Meeting of the American Society of Gene Therapy 2Senesco Announces H1N1 Influenza Survival Test Results in Mice 2Senesco Announces H1N1 Influenza Survival Test Results in Mice 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: